Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. ACN

Go back to Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
(NASDAQ: DNTH) Delayed: 109.13 +1.03 (0.95%)
Previous Close $108.10    52 Week High $ 
Open $105.61    52 Week Low $ 
Day High $111.11    P/E N/A 
Day Low $104.95    EPS $ 
Volume 631,126